Lactic acid bacteria (LAB) produce a wide variety of antimicrobial peptides 28 (bacteriocins) which contribute to the safety and preservation of fermented foods. 29
Introduction 33
Bacteriocin production is a desirable trait among LAB from the perspective of 34 controlling microbial populations in fermented foods in order to extend product shelf-35 life and safety. Bacteriocins produced by LAB are a diverse group of ribosomally-36 synthesized antimicrobial peptides which may be divided into two main groups i.e. 37 class I peptides, which contain post-translational modifications, and class II, or 38 unmodified, peptides [1] . Broad spectrum bacteriocins, such as nisin (class I), inhibit 39
Gram positive food-borne pathogens and spoilage microbes and, when combined with 40 additional hurdles, Gram negative targets [2] . Narrow spectrum bacteriocins can also 41 be of value, for example, lactococcin A (class II) has a lytic effect on sensitive 42 lactococci which, through the release of key enzymes, can accelerate cheese ripening 43 and enhance the development of important organoleptic properties [3] . Bacteriocins 44 may be introduced into a food via in situ production by bacterial starter or adjunct 45 strains in fermented foods, by the addition of purified or semi-purified preparations 46 (e.g. nisin containing powders such as Nisaplin) or as an ingredient based on a 47 7 than that of other lactococcal transconjugants, presumably as a consequence of the 108 additional copies of lcnCD already present [23] . 109 110 Subcloning and expression of bacteriocin genes or gene clusters 111 Subcloning and expression of bacteriocin genes and gene clusters has also been 112 applied as a means of conferring a bacteriocin positive phenotype on LAB strains or 113 to facilitate over-production in a strain that is already a natural bacteriocin producer. 114
Indeed, a particularly effective strategy employed for the overproduction of various 115 class I bacteriocins has been the introduction of additional copies of biosynthesis-116 associated genes to an existing bacteriocin-producing host. This has led to greater 117 yields of nisin [24, 25] and of the individual lacticin 3147 component peptides, Ltn 118
and Ltn, as well as improved yields of bioengineered lacticin 3147 variants [26] . 119
Such studies have also established that the introduction of additional copies of 120 immunity (self-protection) genes can be important to overcome self-toxicity-121 associated limitations when overproducing these peptides. 122
The heterologous production of class II bacteriocins by LAB is dependant on several 123 factors such as the host strain, the expression and secretion systems employed, 124 plasmid stability and copy number and the presence of the cognate bacteriocin 125 immunity genes. While expression systems employing constitutive promoters and 126 inducible promoters (such as the nisin-inducible promoter, (P nisA , of the NIsin 127
Controlled gene Expression (NICE) system [27]) have both been highly exploited, 128 inducible systems have in general been more successful. Regardless of promoter, the 129 strategies involved have varied from cloning of the entire, intact bacteriocin 130 biosynthetic gene cluster [28, 29] to the creation of gene fusions (to facilitate efficient 131 bacteriocin transport) through the exploitation of bacteriocin leader or secretion 132 8 signals [30] [31] [32] [33] [34] [35] [36] [37] . Yeast based platforms have also shown considerable promise. These 133 may be useful for the large-scale production of bacteriocins or for yeast based 134 fermentations [38] [39] [40] [41] . 135
Although these recombination techniques can facilitate increased levels of bacteriocin 136 production and activity, and the construction of improved multi-bacteriocin producing 137 strains, they remain genetically modified organisms (GMO) which may limit their 138 application in the wider Food Industry. 139
140

Bioengineering of bacteriocin peptides 141
There have been a number of instances in which bioengineering of bacteriocin 142 structural genes (through manipulation of the gene in a natural producer or in a strain 143 which produces the bacteriocin heterologously) has been employed with a view to 144 expanding or altering the associated antimicrobial spectrum. This strategy initially 145 evolved from a desire to gain a better appreciation of the importance of specific 146 residues or domains within these peptides, i.e. to assess the negative consequences of 147 mutating these regions. However, this approach has evolved such that strains with 148 greater antimicrobial potency have resulted which can potentially provide for the 149 better control of spoilage or pathogenic microbes. i.e. the producers of lacticin 3147 and lacticin 481, have also been the focus of 168 bioengineering-based strategies. In these cases, the outcomes have been of greater 169 importance from a fundamental science, rather than applied, perspective [60] [61] [62] [63] [64] [65] [66] , with 170 only one example of a partial enhancement having been described to date [64] . Aside 171 from the lantibiotics, as derivatives of the unmodified class II bacteriocins can be 172 generated both synthetically [67, 68] or through heterologous expression [69] [70] [71] [72] [73] [74] [75] [76] [77] with 173 relative ease, there are relatively few examples of instances in which LAB producers 174 of the class II bacteriocins have themselves been engineered. However, the potential 175 exists to reconstitute production of some of the more interesting derivatives in the 176 original host strain should the need or desire arise. 177
It is important to note that while all bioengineering based strategies are valid if the 178 aim is to create bacteriocins for fundamental analyses or applications by the 179 pharmaceutical industry, the application of bioengineered bacteriocin peptides as food 180 preservatives is a bigger obstacle in some jurisdictions. Indeed, many of the strategies 181 employed to produce the engineered bacteriocins described above involve approaches 182 that result in the producer needing to be described as a GMO. However, alternatives 183 exist. Indeed, self cloning of non-pathogenic microorganisms is not considered to lead 184 to a GMO as long as containment of the organism is guaranteed (directive 185 90/219/EC). Accordingly, the temporary introduction of plasmids, the deletion of 186 specific DNA sequences, or introduction of DNA from another micro-organism 187 belonging to the same species fall within the definition of self-cloning. 
